Overview

[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy

Status:
Recruiting

Trial end date:
2021-12-13

Target enrollment:

Participant gender:

Summary

This trial studies how well [18F]-AraG works in detecting T-cell activation in patients with non-small cell lung cancer that has spread to other places in the body (advanced), who are undergoing PD-1/PD-L1-directed therapy. [18F]-AraG is a "radiotracer" which attaches to immune cells directed at the cancer and shines a light that can be seen using a special camera, called a "positron emission tomography" or "PET" scanner. [18F]-AraG may improve the ability to detect a response of the cancer in the body to immunotherapy.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of California, Davis

Collaborators:

CellSight Technologies, Inc.
National Cancer Institute (NCI)

Treatments:

9-arabinofuranosylguanine